ES2862335T3 - Péptidos de AXL modificados y su uso en la inhibición de la señalización de AXL en terapia anti-metastásica - Google Patents

Péptidos de AXL modificados y su uso en la inhibición de la señalización de AXL en terapia anti-metastásica Download PDF

Info

Publication number
ES2862335T3
ES2862335T3 ES17196662T ES17196662T ES2862335T3 ES 2862335 T3 ES2862335 T3 ES 2862335T3 ES 17196662 T ES17196662 T ES 17196662T ES 17196662 T ES17196662 T ES 17196662T ES 2862335 T3 ES2862335 T3 ES 2862335T3
Authority
ES
Spain
Prior art keywords
axl
polypeptide
mer
tyro3
cases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17196662T
Other languages
English (en)
Spanish (es)
Inventor
Amato J Giaccia
Erinn Bruno Rankin
Jennifer R Cochran
Douglas Jones
Mihalis Kariolis
Katherine Fuh
Yu Miao
Susan Hershenson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aravive Biologics Inc
Leland Stanford Junior University
Original Assignee
Aravive Biologics Inc
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50934967&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2862335(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aravive Biologics Inc, Leland Stanford Junior University filed Critical Aravive Biologics Inc
Application granted granted Critical
Publication of ES2862335T3 publication Critical patent/ES2862335T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES17196662T 2012-12-14 2013-12-12 Péptidos de AXL modificados y su uso en la inhibición de la señalización de AXL en terapia anti-metastásica Active ES2862335T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261737276P 2012-12-14 2012-12-14

Publications (1)

Publication Number Publication Date
ES2862335T3 true ES2862335T3 (es) 2021-10-07

Family

ID=50934967

Family Applications (2)

Application Number Title Priority Date Filing Date
ES17196662T Active ES2862335T3 (es) 2012-12-14 2013-12-12 Péptidos de AXL modificados y su uso en la inhibición de la señalización de AXL en terapia anti-metastásica
ES13862780T Active ES2665323T7 (es) 2012-12-14 2013-12-12 Péptidos de AXL modificados y su uso en la inhibición de la señalización de AXL en terapia anti-metastásica

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES13862780T Active ES2665323T7 (es) 2012-12-14 2013-12-12 Péptidos de AXL modificados y su uso en la inhibición de la señalización de AXL en terapia anti-metastásica

Country Status (11)

Country Link
US (3) US9822347B2 (enExample)
EP (2) EP3326622B1 (enExample)
JP (2) JP6345690B2 (enExample)
AU (3) AU2013359179B2 (enExample)
CA (1) CA2894539C (enExample)
DK (2) DK3326622T3 (enExample)
ES (2) ES2862335T3 (enExample)
FI (1) FI2931265T6 (enExample)
NO (1) NO3049208T3 (enExample)
PT (2) PT3326622T (enExample)
WO (1) WO2014093690A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3056999A1 (en) * 2010-01-22 2011-07-28 Amato J. Giaccia Inhibition of axl signaling in anti-metastatic therapy
US9074192B2 (en) * 2010-01-22 2015-07-07 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL signaling in anti-metastatic therapy
US9879061B2 (en) 2011-12-15 2018-01-30 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis
US9822347B2 (en) 2012-12-14 2017-11-21 The Board Of Trustees Of The Leland Stanford Junior University Modified AXL peptides and their use in inhibition of AXL signaling in anti-metastatic therapy
CA2909669C (en) 2014-10-20 2023-12-12 Ruga Corporation Antiviral activity of gas6 inhibitor
EP3233902B1 (en) * 2014-12-18 2020-09-09 Aravive Biologics, Inc. Antifibrotic activity of gas6 inhibitor
EP3703731A4 (en) * 2017-11-04 2021-07-21 Aravive Biologics, Inc. METHOD OF TREATMENT OF METASTATIC CANCER USING AXL DECOY RECEPTORS
WO2023039254A1 (en) * 2021-09-11 2023-03-16 Aravive Inc Methods of treating locally advanced or metastatic pancreatic adenocarcinoma using axl decoy receptors as first-line therapy

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
US5538861A (en) 1994-07-29 1996-07-23 Amgen Inc. DNA encoding a stimulating factor for the axl receptor
US20030082767A1 (en) 1997-09-18 2003-05-01 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1382969A1 (en) 2002-07-17 2004-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Diagnosis and prevention of cancer cell invasion
AU2003304180A1 (en) 2002-09-24 2005-01-04 Dow, Kenneth, Centocor, Inc. Growth arrest specific gene 6 peptides, antibodies, compositions, methods and uses
US20070142273A1 (en) 2003-04-18 2007-06-21 Sherif Daouti Methods and compositions targeting tyrosine kinases for the diagnosis and treatment of osteoarthritis
JP2005278631A (ja) 2004-03-04 2005-10-13 National Institute Of Advanced Industrial & Technology Ａｘｌリガンド結合領域蛋白質、その製造方法及びそれを用いたスクリーニング方法
WO2006058202A2 (en) 2004-11-24 2006-06-01 The Regents Of The University Of Colorado Mer diagnostic and therapeutic agents
US7932032B2 (en) 2005-05-02 2011-04-26 Toray Industries, Inc. Method for diagnosing esophageal cancer
EP2114983B8 (en) * 2007-02-07 2015-02-18 The Regents of the University of Colorado, A Body Corporate Axl tyrosine kinase inhibitors and methods of making and using the same
AU2008240188A1 (en) 2007-04-13 2008-10-23 Supergen, Inc. Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders
EP2170395A1 (en) 2007-07-02 2010-04-07 Wyeth LLC Modulators of axl for use in treating bone disorders
WO2010014755A1 (en) 2008-07-29 2010-02-04 The Regents Of The University Of Colorado Methods and compounds for enhancing anti-cancer therapy
BRPI0923442A2 (pt) * 2008-12-19 2016-01-12 Novartis Ag polipeptídeos solúveis para uso em tratamento de distúrbio autoimunes e inflamatórios.
AR076564A1 (es) 2009-05-11 2011-06-22 U3 Pharma Gmbh Anticuerpos humanizados de axl(receptor de tirosina quinasa)
US9074192B2 (en) * 2010-01-22 2015-07-07 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL signaling in anti-metastatic therapy
CA3056999A1 (en) 2010-01-22 2011-07-28 Amato J. Giaccia Inhibition of axl signaling in anti-metastatic therapy
CA2817197C (en) 2010-11-08 2020-08-04 The Board Of Trustees Of The Leland Stanford Junior University Fusion proteins comprising an engineered knottin peptide and uses thereof
US9879061B2 (en) 2011-12-15 2018-01-30 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis
WO2014093707A1 (en) 2012-12-14 2014-06-19 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of axl signaling in primary tumor therapy
US9822347B2 (en) * 2012-12-14 2017-11-21 The Board Of Trustees Of The Leland Stanford Junior University Modified AXL peptides and their use in inhibition of AXL signaling in anti-metastatic therapy
WO2015030849A1 (en) * 2013-08-30 2015-03-05 The Board Of Trustees Of The Leland Stanford Junior University High-affinity binding to gas6
CA2909669C (en) * 2014-10-20 2023-12-12 Ruga Corporation Antiviral activity of gas6 inhibitor
EP3233902B1 (en) * 2014-12-18 2020-09-09 Aravive Biologics, Inc. Antifibrotic activity of gas6 inhibitor

Also Published As

Publication number Publication date
US9822347B2 (en) 2017-11-21
US20150315553A1 (en) 2015-11-05
CA2894539A1 (en) 2014-06-19
NO3049208T3 (enExample) 2018-04-14
CA2894539C (en) 2021-09-28
EP3326622B1 (en) 2021-01-20
PT2931265T (pt) 2018-04-16
US20220220458A1 (en) 2022-07-14
WO2014093690A1 (en) 2014-06-19
JP6832887B2 (ja) 2021-02-24
DK2931265T3 (en) 2018-04-16
EP2931265B3 (en) 2023-04-05
EP2931265B1 (en) 2018-01-31
AU2017272193A1 (en) 2017-12-21
AU2019210662A1 (en) 2019-08-22
HK1256071A1 (en) 2019-09-13
PT3326622T (pt) 2021-04-07
AU2013359179A1 (en) 2015-07-02
FI2931265T6 (fi) 2023-05-23
EP3326622A1 (en) 2018-05-30
JP6345690B2 (ja) 2018-06-20
ES2665323T7 (es) 2023-06-15
AU2013359179B2 (en) 2017-10-05
US11136563B2 (en) 2021-10-05
ES2665323T3 (es) 2018-04-25
JP2018154641A (ja) 2018-10-04
AU2019210662B2 (en) 2021-07-01
US20180030422A1 (en) 2018-02-01
EP2931265A4 (en) 2016-08-31
JP2016510309A (ja) 2016-04-07
DK3326622T3 (da) 2021-04-06
EP2931265A1 (en) 2015-10-21
DK2931265T6 (da) 2023-05-01

Similar Documents

Publication Publication Date Title
ES2665323T7 (es) Péptidos de AXL modificados y su uso en la inhibición de la señalización de AXL en terapia anti-metastásica
ES2928111T3 (es) Inhibición de la señalización AXL en terapia antimetastásica
US9879061B2 (en) Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis
ES2834618T3 (es) Actividad antifibrótica del inhibidor de GAS6
US20150315552A1 (en) Inhibition of AXL Signaling in Primary Tumor Therapy
US9074192B2 (en) Inhibition of AXL signaling in anti-metastatic therapy
KR20200143385A (ko) Mospd2와, t 세포 또는 nk 세포 특이적 분자에 대한 2중 특이적 항체
US20160266136A1 (en) High-affinity binding to gas6
HK1256071B (en) Modified axl peptides and their use in inhibition of axl signaling in anti-metastatic therapy